MedTrace Logo

Vismodegib for Treatment of Basal Cell Carcinoma

NCT01543581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-09-26

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to assess, using Mohs micrographic surgery (MMS) at the end of treatment, the efficacy (primary) and safety (secondary) of vismodegib compared to placebo in the oral adjunctive pre surgical treatment of basal cell carcinoma. A secondary objective is to assess how often and in what types of lesions does pre surgical treatment with vismodegib result in complete eradication of the tumor.

Conditions

Interventions

DRUG

Vismodegib

Oral vismodegib, 150mg per day for 12 weeks.

DRUG

Placebo

Sponsors & Collaborators

  • Abel Torres, MD

    lead OTHER

Principal Investigators

  • Abel Torres, MD · Professor and Chairman, Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-06-30
Completion
2013-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543581 on ClinicalTrials.gov